INDOCO REMEDIES Financial Statement Analysis
|
||
|
The Revenues of INDOCO REMEDIES have decreased by -8.38% YoY .
The Earnings Per Share (EPS) of INDOCO REMEDIES has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
INDOCO REMEDIES Last 5 Annual Financial Results
[BOM: 532612|NSE : INDOCO]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹1,665 Cr | ₹1,817 Cr | ₹1,669 Cr | ₹1,541 Cr | ₹1,242 Cr |
| Expenses | ₹1,566 Cr | ₹1,581 Cr | ₹1,383 Cr | ₹1,215 Cr | ₹1,023 Cr |
| Operating Profit (Excl OI) | ₹99 Cr | ₹236 Cr | ₹286 Cr | ₹326 Cr | ₹218 Cr |
| Other Income | ₹5.45 Cr | ₹19 Cr | ₹2.63 Cr | ₹3.42 Cr | ₹9.06 Cr |
| Interest | ₹66 Cr | ₹39 Cr | ₹25 Cr | ₹14 Cr | ₹22 Cr |
| Depreciation | ₹114 Cr | ₹92 Cr | ₹71 Cr | ₹79 Cr | ₹73 Cr |
| Profit Before Tax | ₹-74 Cr | ₹136 Cr | ₹193 Cr | ₹237 Cr | ₹132 Cr |
| Profit After Tax | ₹-78 Cr | ₹97 Cr | ₹142 Cr | ₹155 Cr | ₹93 Cr |
| Consolidated Net Profit | ₹-74 Cr | ₹98 Cr | ₹142 Cr | ₹155 Cr | ₹93 Cr |
| Earnings Per Share (Rs) | ₹-7.99 | ₹10.68 | ₹15.44 | ₹16.80 | ₹10.10 |
| PAT Margin (%) | -4.68 | 5.34 | 8.53 | 10.05 | 7.49 |
| ROE(%) | -7.34 | 9.09 | 14.72 | 18.50 | 12.85 |
| ROCE(%) | -0.43 | 11.25 | 17.50 | 23.03 | 15.67 |
| Total Debt/Equity(x) | 0.96 | 0.59 | 0.31 | 0.27 | 0.34 |
Key Financials |
||
| Market Cap | : | ₹ 2,414.3 Cr |
| Revenue (TTM) | : | ₹ 1,723.3 Cr |
| Net Profit(TTM) | : | ₹ -115.3 Cr |
| EPS (TTM) | : | ₹ -12.5 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| INDOCO REMEDIES | -1.7% | -11.1% | -13.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.5% | 6.2% | -4.2% |
| DIVIS LABORATORIES | -2.7% | -0.7% | 11% |
| CIPLA | 1.2% | -1.4% | -4.1% |
| TORRENT PHARMACEUTICALS | 0.6% | 9.1% | 19.7% |
| DR REDDYS LABORATORIES | 3.9% | 0.6% | -3.7% |
| MANKIND PHARMA | 1.4% | -6.9% | -15.2% |
| ZYDUS LIFESCIENCES | -0.3% | -3.6% | -2.5% |
| LUPIN | 3.4% | 6.1% | -2.4% |
INDOCO REMEDIES Revenues
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | -8.38 % |
| 5 Yr CAGR | 7.61 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,665 Cr | -8.38 | |
| Mar2024 | ₹1,817 Cr | 8.91 | |
| Mar2023 | ₹1,669 Cr | 8.30 | |
| Mar2022 | ₹1,541 Cr | 24.10 | |
| Mar2021 | ₹1,242 Cr | - | |
INDOCO REMEDIES Operating Profit
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | -58.02 % |
| 5 Yr CAGR | -17.89 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹99 Cr | -58.02 | |
| Mar2024 | ₹236 Cr | -17.35 | |
| Mar2023 | ₹286 Cr | -12.32 | |
| Mar2022 | ₹326 Cr | 49.43 | |
| Mar2021 | ₹218 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -54.19 % |
| 5 Yr CAGR | -23.71 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 5.96% | -54.19 | |
| Mar2024 | 13.01% | -24.10 | |
| Mar2023 | 17.14% | -19.04 | |
| Mar2022 | 21.17% | 20.35 | |
| Mar2021 | 17.59% | - | |
INDOCO REMEDIES Profit After Tax
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹-74 Cr | Negative | |
| Mar2024 | ₹98 Cr | -30.78 | |
| Mar2023 | ₹142 Cr | -8.11 | |
| Mar2022 | ₹155 Cr | 66.37 | |
| Mar2021 | ₹93 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | -4.68 % | Negative | |
| Mar2024 | 5.34 % | -37.40 | |
| Mar2023 | 8.53 % | -15.12 | |
| Mar2022 | 10.05 % | 34.18 | |
| Mar2021 | 7.49 % | - | |
INDOCO REMEDIES Earnings Per Share (EPS)
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹-7.99 | Negative | |
| Mar2024 | ₹11 | -30.83 | |
| Mar2023 | ₹15 | -8.10 | |
| Mar2022 | ₹17 | 66.34 | |
| Mar2021 | ₹10 | - | |
INDOCO REMEDIES Return on Capital Employed (ROCE)
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | -0.43% | Negative | |
| Mar2024 | 11.25% | -35.71 | |
| Mar2023 | 17.5% | -24.01 | |
| Mar2022 | 23.03% | 46.97 | |
| Mar2021 | 15.67% | - | |
INDOCO REMEDIES Share Price vs Sensex
| Current Share Price | : | ₹261.9 |
| Current MarketCap | : | ₹ 2,414.3 Cr |
| Updated EOD on | : | Nov 14,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDOCO REMEDIES | -1.7% |
-11.1% |
-13.2% |
| SENSEX | 1.6% |
2.7% |
6.3% |
INDOCO REMEDIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | 0.7% | -0% | 1.3% |
| BSE SMALLCAP | 0.2% | -0% | -4.7% |
No NSE index found
You may also like the below Video Courses
FAQ about INDOCO REMEDIES Financials
How the annual revenues of INDOCO REMEDIES have changed ?
The Revenues of INDOCO REMEDIES have decreased by -8.38% YoY .
How the Earnings per Share (EPS) of INDOCO REMEDIES have changed?
The Earnings Per Share (EPS) of INDOCO REMEDIES has decreased by Negative YoY .
Check out Intrinsic Value of Peers of INDOCO REMEDIES
Compare Stock Analytics of Peers of INDOCO REMEDIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
